Wait...

Online Export Import Data Search

Recent Searches: No Recent Searches
Complete Training Video : Click Here

Cadila Healthcare share price hits 52-week high on USFDA nod for cancer drug.


Date: 10-04-2020
Subject: Cadila Healthcare share price hits 52-week high on USFDA nod for cancer drug
Cadila Healthcare share price touched 52-week high of Rs 378, rising 8 percent intraday on April 9 after the company received final approval from the US drug regulator for a blood cancer drug.

Zydus Cadila has received final approval from the US Food and Drug Administration to market Imatinib Mesylate Tablets, 100 mg and 400 mg, as per a company release.

This medication is used to treat certain types of leukemia (blood cancer), bone marrow disorders, skin cancer and tumours of the stomach and digestive system.

The drug will be manufactured at the group’s Ahmedabad SEZ facility, it added.

At 1147 hours, Cadila Healthcare was quoting at Rs 355.70, up Rs 5.75, or 1.64 percent, on the BSE.

Source:- moneycontrol.com

Get Sample Now

Which service(s) are you interested in?
 Export Data
 Import Data
 Both
 Buyers
 Suppliers
 Both
OR
 Exim Help
+




Exim Guru Copyright © 1999-2020 Exim Guru. All Rights Reserved.
The information presented on the site is believed to be accurate. However, InfodriveIndia takes no legal responsibilities for the validity of the information.
Please read our Terms of Use and Privacy Policy before you use this Export Import Data Directory.

EximGuru.com

C/o InfodriveIndia Pvt Ltd
F-19, Pocket F, Okhla Phase-I
Okhla Industrial Area
New Delhi - 110020, India
Phone : 011 - 40703001